Captrust Financial Advisors Precision Biosciences Inc Transaction History

Captrust Financial Advisors

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.29 - $0.45 $2,559 - $3,971	-8,826 Reduced 7.22%	113,484 $40,000
Q3 2023 Nov 14, 2023	SELL	$0.34 - $0.69 $256 - $520	-755 Reduced 0.61%	122,310 $41,000
Q2 2023 Aug 14, 2023	SELL	$0.52 - $0.91 $14,660 - $25,656	-28,194 Reduced 18.64%	123,065 $65,000
Q1 2023 May 15, 2023	SELL	$0.7 - $1.41 $1,994 - $4,018	-2,850 Reduced 1.85%	151,259 $113,000
Q4 2022 Feb 15, 2023	SELL	$0.97 - $45.0 $126 - $5,850	-130 Reduced 0.08%	154,109 $183,000
Q3 2022 Nov 16, 2022	SELL	$1.22 - $40.8 $61 - $2,039	-50 Reduced 0.03%	154,239 $201,000
Q2 2022 Aug 16, 2022	BUY	$1.15 - $3.34 $1,532 - $4,452	1,333 Added 0.87%	154,289 $247,000
Q1 2022 May 16, 2022	BUY	$2.96 - $7.76 $12,082 - $31,676	4,082 Added 2.74%	152,956 $471,000
Q4 2021 Feb 14, 2022	BUY	$7.4 - $11.66 $20,646 - $32,531	2,790 Added 1.91%	148,874 $1.1 Million
Q3 2021 Nov 16, 2021	BUY	$9.18 - $14.15 $1.34 Million - $2.06 Million	145,501 Added 24957.29%	146,084 $1.69 Million
Q2 2021 Aug 16, 2021	BUY	$8.07 - $12.52 $3,090 - $4,795	383 Added 191.5%	583 $7,000
Q1 2021 May 17, 2021	BUY	$8.57 - $15.79 $1,714 - $3,158	200 New	200 $2,000

2.56M

Ticker DTIL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 110,818,000
Market Cap $539M
Description
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific ...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.